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respectively. In comparison to that our study shows same or no
inferior outcomewhich proves the drug combination is as effective
as thrombolysis.
Conclusion: Inj. Heparin along with DAPT on FMC following acute
MI yields similar results as thrombolysis with signiﬁcant improve-
ment in TIMI ﬂow of the IRA and also signiﬁcant reduction of the
slow ﬂow, no ﬂow or other complications during PPCI.
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Background: Triple antiplatelet therapy (TAT) has been found to be
superior to dual antiplatelet therapy (DAT) in patients with acute
coronary syndromes undergoing percutaneous coronary interven-
tion (PCI) with drug-eluting stents (DES).
Methods: A prospective, double blinded, randomized study was
conducted in ACS patients undergoing PCI with DES and control
population without any coronary artery disease (CAD). ACS
patients were randomized into DAT group (DAT, aspirin + clopido-
grel) and TAT group (TAT, aspirin + clopidogrel + cilostazol).
Patients in the TAT group were given loading doses of 200 mg of
cilostazol peri-procedurally (within 6–12 h prior to the procedure to
1–2 h post-procedure) followed by 100 mg/day for atleast six
months. Patients were evaluated at baseline, at seven days and
six months intervals for clinical outcomes. ADP, collagen, and
epinephrine-induced platelet aggregation was measured at base-
line and at seven days interval.
Results: There were no signiﬁcant differences in the baseline
characteristics in both the groups. Comparison between dual
and triple antiplatelet groups showed signiﬁcantly greater inhibi-
tion of ADP-induced platelet aggregation in the triple therapy
group at seven days interval (19.05  14.06% vs 36.20  25.0%,
p = 0.02) and trend towards greater platelet inhibition at baseline
between two groups (19.2  27.32% vs 33.0  22.01%, p = 0.077),
respectively. Triple therapy group had lesser number of patients
who had hyporesposiveness to antiplatelet therapy (deﬁned as
inhibition of less than 50% of ADP, collagen or epinephrine induced
platelet aggregation). The study was underpowered for assessing
MACE outcomes.
Conclusions: Cilostazol is a signiﬁcant add on therapy to standard
DAT with aspirin and high maintenance dose clopidogrel. Its
loading dose of 200 mg, followed by 100 mg BD provides greater
inhibition of ADP-induced platelet aggregation without increase in
bleeding complications or tolerance issues.
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The objective of this study is to evaluate outcome of the 20 patients
who underwent alcoholic septal ablation for symptomatic HOCM
at our hospital.
Background: LVOT obstruction is an important determinant of
clinical symptoms in patients with HOCM. Alcohol septal ablation
shown to decrease LVOT gradient and resolution of symptoms
immediately after the procedure and on midterm follow-up.
Methods: 20 patients with HOCM who underwent alcoholic septal
ablation at our hospital and completed one-year follow-up are
described. A detailed analysis of clinical examination and Echo
Doppler carried out.
Results: The mean age of the study group was 54  16 years (range
26–76 yrs). All patients had refractory symptoms before enrolment.
90% patients had NYHA class III/IV symptoms at baseline com-
pared to none at 1 year. Only 20% of patients were either receiving
beta-blockers or CCBs on follow-up. The resting LVOT gradient
decreased from 70  20 mmHg to 10  6 mmHg. These changes are
associated with decreased septal thickness and preserved systolic
function. Three patients (15%) developed complete heart block,
two patients improved after TPI and one required permanent
pacemaker. One patient (5%) developed acute anterior wall myo-
cardial infarction and taken for emergency CABG, but died during
post-operatively.
Conclusion: Alcohol septal ablation associated with decreased
septal thickness and preserved systolic function. This procedure
is an effective therapeutic procedure with favorable outcome.
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One hundred patients who underwent PCI with Yukon Choice Flex
(Indigenous stent) between September 2014 to February 2015 have
been studied retrospectively. There were 86 (86%) males and 14
(14%) females with mean age 59.12  12.33 (28–84 years). Risk
factors were hypertension – 50(50%), type 2 DM – 42(42%), smoking
28(28%), CKD 8(8%), and dyslipidemia 14 (14%). Clinical presenta-
tion was ACS with STEMI – 44 (44%), NSTEMI 30 (30%), unstable
angina – 14 (14%). Chronic stable angina was present in 12 (12%)
patients. Mean LVEF of this group was 50.3  9.3% (range 21–60%).
Three patients with STEMI presented in cardiogenic shock.
Coronary angio proﬁle revealed single vessel disease in 54 (54%)
and multi-vessel disease in 46 (46%) patients. PCI was done
through femoral artery in 80 (80%) and right radial in 20 (20%)
patients. Weight adjusted heparin was used as anticoagulant.
Antiplatelet therapy in the form of asprin, clopidogrel, or prasugrel
was used in patients at operators discretion.
Primary angioplasty was done in 16 (16%) patients. IABP support
was used in 6 (6%). GP IIb/IIIa inhibitors were used in 76 (76%)
patients, of which 52 (66%) received tiroﬁban, while 26 (34%)
received abciximab.
All patients received biodegradable polymer sirolimus eluting
Yukon Choice Flex stent. Average stent diameter was 2.92
 0.44 mm. Average stent length was 24.53  8.47 mm. Average
no. of stents deployed per patient was 1.66  0.86. Average dura-
tion of hospital stay was 3  1.31 days. One patient who was in
cardiogenic shock died during the hospital stay. There was no
other MACE during the hospitalization. Two patients were
admitted with subacute stent thrombosis at 7 and 20 days,
requiring re-dilatation. Patients were followed clinically and
telephonically between 6 and 9 months (mean 8.23  7.03
months).
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